SMS Pharmaceuticals Limited
All news and filings related to SMS Pharmaceuticals Limited.
View all news & filings- Medium impact
SMS Pharma Holds 38th AGM: Approves Financials, Dividend, MD Re-appointment
SMS Pharmaceuticals Limited held its 38th AGM on September 29, 2026. The meeting approved financial statements for FY26, declared a dividend for FY25-26, and re-appointed the MD. Related party transactions and a loan to a subsidiary were also approved. E-voting results will be announced within two days.
Read the summary - Low impact
SMS Pharmaceuticals: Trading Window Closed for Q2FY27 Results
SMS Pharmaceuticals Limited will close its trading window from October 1, 2026. The window will reopen 48 hours after the declaration of financial results for the second quarter and half-year ended September 30, 2026. The board meeting date will be announced later.
Read the summary - Low impact
SMS Pharmaceuticals to Attend Emkay Global Investors Meeting on Sep 15, 2026
SMS Pharmaceuticals management will attend a group investor meeting hosted by Emkay Global Investors in Hyderabad on September 15, 2026. Discussions will focus on public domain information, with no unpublished price-sensitive details to be disclosed.
Read the summary - Low impact
SMS Pharmaceuticals Announces 38th AGM on Sep 29, 2026; Proposes ₹0.40 Dividend
SMS Pharmaceuticals will hold its 38th AGM on September 29, 2026, via VC/OAVM. The company will distribute its FY25-26 Integrated Annual Report. A dividend of ₹0.40 per share is proposed, with a record date of September 22, 2026.
Read the summary - Low impact
SMS Pharmaceuticals Files Business Responsibility and Sustainability Report for FY 2025-26
SMS Pharmaceuticals Limited has filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report covers ESG disclosures, operational details, employee information, and risk management strategies. It details the company's approach to supply chain, health and safety, governance, climate action, and resource management, forming part of the Annual Report.
Read the summary - Low impact
SMS Pharmaceuticals to hold 38th AGM on Sept 29, 2026
SMS Pharmaceuticals Limited will hold its 38th Annual General Meeting on September 29, 2026, via video conference. The record date for dividend and e-voting eligibility is September 22, 2026. Remote e-voting will be open from September 25 to September 28, 2026.
Read the summary - Medium impact
SMS Pharmaceuticals: CARE Ratings Reaffirms 'CARE A; Stable' Outlook on ₹570 Crore Facilities
SMS Pharmaceuticals Limited's long-term bank facilities of ₹570.07 crore have been reaffirmed with a 'CARE A; Stable' rating by CARE Ratings. The outlook was revised from Positive to Stable. Short-term facilities of ₹52.83 crore were reaffirmed at 'CARE A1'. The ratings consider FY26 audited and Q1FY27 performance.
Read the summary - Low impact
SMS Pharma Ltd. schedules 38th Annual General Meeting for Sep 29, 2026
SMS Pharmaceuticals Limited will hold its 38th Annual General Meeting on September 29, 2026. The meeting will be conducted via Video Conference or Other Audio Visual Means. Newspaper advertisements have been published on August 29, 2026.
Read the summary - Low impact
SMS Pharmaceuticals Revises 38th AGM Date to Sept 29, Sets Record Date for Dividend
SMS Pharmaceuticals has rescheduled its 38th AGM to September 29, 2026. The record date for dividend eligibility is now September 22, 2026. Book closure is from September 23 to September 29, 2026.
Read the summary - Medium impact
SMS Pharmaceuticals: 38th AGM Rescheduled to Sep 29, Dividend Record Date Sep 22
SMS Pharmaceuticals Limited has rescheduled its 38th AGM to September 29, 2026. The book closure period is from September 23 to September 29, 2026. The record date for dividend eligibility is now September 22, 2026.
Read the summary - Low impact
SMS Pharma Announces 38th AGM on Sep 23, 2026, via Video Conference
SMS Pharmaceuticals Limited will hold its 38th AGM on September 23, 2026, via video conference. The record date for dividend entitlement is September 16, 2026. Shareholders must submit declarations by September 9, 2026.
Read the summary - Low impact
SMS Pharma to deduct TDS on Rs. 0.40/share final dividend for FY26
SMS Pharmaceuticals Limited recommended a final dividend of ₹0.40 per equity share for FY25-26. The AGM to approve this dividend is on September 23, 2026. The record date is September 16, 2026. Shareholders must submit TDS-related documents by September 9, 2026, to avail benefits.
Read the summary - Low impact
SMS Pharmaceuticals Limited Publishes Q1 FY27 Financial Results in Newspapers
SMS Pharmaceuticals Limited published its audited standalone and consolidated financial results for Q1 FY27, ending June 30, 2026. The results were advertised in The Financial Express and Andhra Prabha on August 1, 2026, and are also available on the company's website.
Read the summary - Medium impact
SMS Pharma Q1FY27: Revenue up 6% YoY to ₹207 Cr, PAT up 8% to ₹20 Cr
SMS Pharmaceuticals Limited's Q1FY27 revenue grew 6% YoY to ₹207 crore, with PAT up 8% to ₹20 crore. The company completed 4 DMF/CEP filings and is on track for its FY27 target. A ₹280 crore capex program is underway. The board approved a ₹50 crore loan infusion into subsidiary SMS Peptides.
Read the summary - Medium impact
SMS Pharma Q1FY27 Revenue Up 6% to ₹207 Cr, PAT Grows 8% to ₹20.2 Cr
SMS Pharma reported Q1FY27 revenue of ₹207 crore, up 6% YoY, with PAT at ₹20.2 crore, up 8% YoY. EBITDA margin remained at 20%. The company completed 4 DMF/CEP filings and is on track for its FY27 target of 10 filings. A ₹50 crore loan will be infused into subsidiary SMS Peptides Private Limited.
Read the summary - Medium impact
SMS Pharma Q1 FY27 Results: Profit ₹21.13 Cr, MD Reappointed, ₹50 Cr Loan to Subsidiary
SMS Pharmaceuticals Limited reported Q1 FY27 standalone net profit of ₹21.13 Cr, up from ₹18.21 Cr YoY. Consolidated net profit was ₹20.91 Cr. The Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman and MD for 5 years from Oct 1, 2026. A loan of up to ₹50 Cr will be given to subsidiary SMS Peptides Private Limited. The 38th AGM is scheduled for Sep 23, 2026.
Read the summary - Medium impact
SMS Pharma Board Approves Q1 FY27 Results, Reappoints MD, Approves ₹50 Cr Loan
SMS Pharmaceuticals Limited reported Q1 FY27 results with standalone net profit at ₹2,113.26 Lakhs and consolidated net profit at ₹2,090.90 Lakhs. The Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman and MD for five years from Oct 1, 2026. A loan of up to ₹50 Crores to subsidiary SMS Peptides Private Limited was also approved. The 38th AGM is scheduled for Sep 23, 2026.
Read the summary - Medium impact
SMS Pharma Q1 FY27 Results: Profit ₹211 Crore; MD Re-appointed
SMS Pharmaceuticals Limited reported Q1 FY27 results with standalone net profit at ₹21.13 crore and consolidated net profit at ₹20.91 crore. The Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director for five years from October 1, 2026. A loan of up to ₹50 crore to a subsidiary was also approved. The 38th AGM is scheduled for September 23, 2026.
Read the summary - Medium impact
SMS Pharma Q1 FY27 Results: Profit Rs 21.13 Cr, MD Re-appointed, Rs 50 Cr Loan to Subsidiary
SMS Pharmaceuticals Limited reported Q1 FY27 results with a net profit of ₹21.13 crore (standalone) and ₹20.91 crore (consolidated). The Board approved the re-appointment of Mr. Ramesh Babu Potluri as CMD for five years from Oct 1, 2026. A loan of up to ₹50 crore will be given to subsidiary SMS Peptides. The 38th AGM is on Sept 23, 2026.
Read the summary - Medium impact
SMS Pharma Board Approves Q1 FY27 Results, Reappoints MD, Approves ₹50 Cr Loan
SMS Pharmaceuticals Limited's Board approved Q1 FY27 results. The 38th AGM is on September 23, 2026. Mr. Ramesh Babu Potluri was re-appointed as Chairman and MD for five years from Oct 1, 2026. The company will provide a loan of up to ₹50 Crores to subsidiary SMS Peptides Private Limited, subject to shareholder approval.
Read the summary - Low impact
SMS Pharma Publishes Newspaper Advertisement for IEPF Share Transfer
SMS Pharmaceuticals Limited published newspaper advertisements on July 22, 2026, regarding the transfer of shares with unpaid dividends for FY 2018-19 to the IEPF. Shareholders have until October 25, 2026, to claim their dues before the transfer.
Read the summary - Low impact
SMS Pharma Reminds Shareholders About Share Transfer to IEPF
SMS Pharmaceuticals Limited is reminding shareholders about the compulsory transfer of shares to the IEPF if dividends remain unclaimed for seven years. Shareholders must claim their dividends by October 25, 2026. Failure to do so will lead to shares being transferred to the IEPF.
Read the summary - Medium impact
SMS Pharmaceuticals Limited: Arrest Made in Share Impersonation Case
SMS Pharmaceuticals Limited reported an arrest in a case of share impersonation. One individual was apprehended by police and remanded to judicial custody on July 19, 2026, following a complaint lodged by the company regarding fraudulent share claims. The investigation is ongoing.
Read the summary - Low impact
SMS Pharmaceuticals Ltd. Files SEBI Compliance Certificate for Q1 FY27
SMS Pharmaceuticals Limited submitted a compliance certificate for Q1 FY27 under SEBI regulations. The company's RTA confirmed timely dematerialization of securities and updated ownership records for the period ending June 30, 2026.
Read the summary - Medium impact
SMS Pharma Q4 FY26: Revenue ₹238 Cr, PAT ₹33 Cr; Guides 15% Growth
SMS Pharmaceuticals reported Q4 FY26 revenue of ₹238 crore and full-year revenue of ₹887 crore, a 13% increase. Full-year EBITDA rose 23% to ₹171 crore with margins improving to 20%. PAT for the full year was ₹102 crore, up 47%. The company is investing ₹280 crore in expansion and guides for 15% revenue growth in FY27.
Read the summary - Low impact
SMS Pharmaceuticals: Audio Recording of Investor Call on Q4 FY26 Results Available
SMS Pharmaceuticals has released the audio recording of its investor conference call concerning the financial results for the fourth quarter and year ended March 31, 2026. The recording is accessible on the company's website.
Read the summary - Low impact
SMS Pharmaceuticals Limited Publishes Q4 & FY26 Financial Results
SMS Pharmaceuticals Limited announced its audited standalone and consolidated financial results for the fourth quarter and fiscal year ended March 31, 2026. The results were approved by the Board on May 22, 2026, and published on May 24, 2026. The information is available on the company website.
Read the summary - Medium impact
SMS Pharma FY26 PAT Surges 47% to ₹102 Crore; Recommends ₹0.40 Dividend
SMS Pharmaceuticals Limited reported FY26 PAT of ₹102 crore, up 47% YoY, driven by backward integration. FY26 revenue grew 13% to ₹887 crore, with EBITDA margin at 19%. The company recommended a final dividend of ₹0.40 per share. Q4FY26 PAT was ₹20 crore. A ₹280 crore capex program is on track for completion by FY27.
Read the summary - High impact
SMS Pharma FY26 PAT Surges 48% to ₹102 Cr; Board Recommends ₹0.40 Dividend
SMS Pharmaceuticals Limited reported FY26 PAT growth of 48% to ₹102 crore, with EBITDA margin expanding to 19%. Revenue grew 13% to ₹886.87 crore. The Board recommended a final dividend of ₹0.40 per share. A ₹280 crore capex program is on track for FY27 completion.
Read the summary - Medium impact
SMS Pharmaceuticals Announces Q4 FY26 Results, Schedules Investor Call for May 27
SMS Pharmaceuticals announced Q4 and full-year FY26 results on May 22, 2026. The company will host an investor conference call on May 27, 2026, at 11:00 am IST to discuss financial performance. Details for joining the call are provided.
Read the summary - Medium impact
SMS Pharma Board Approves FY26 Results, Recommends 40% Dividend, Shifts Office
SMS Pharmaceuticals Limited reported audited financial results for FY26. The company recommended a final dividend of 40% (Re. 0.40 per share). The registered office will be shifted effective May 25, 2026. Cost and Internal Auditors were appointed for FY27. The Board meeting concluded on May 22, 2026.
Read the summary - Medium impact
SMS Pharmaceuticals Q4 FY26 Results: Profit Up, Dividend Recommended, Office Shift Approved
SMS Pharmaceuticals declared audited Q4 FY26 results with an unmodified audit opinion. The company recommended a final dividend of ₹0.40 per share for FY26. The registered office will shift to Kondapur, Hyderabad, effective May 25, 2026. Cost and Internal Auditors were appointed for FY27.
Read the summary - Medium impact
SMS Pharmaceuticals Recommends 40% Final Dividend; Approves Financial Results & Office Shift
SMS Pharmaceuticals declared audited financial results for Q4FY26 and FY26. The company recommended a final dividend of ₹0.40 per share. The Board also approved the shifting of the registered office effective May 25, 2026, and the appointment of new cost and internal auditors for FY27.
Read the summary - Medium impact
SMS Pharma FY26 Revenue ₹886.87 Crore, Recommends 40% Dividend
SMS Pharmaceuticals Limited reported FY26 revenue of ₹886.87 crore and net profit of ₹87.61 crore (standalone). The company recommended a final dividend of 40% (₹0.40 per share). The registered office will be shifted effective May 25, 2026. Cost and Internal Auditors were appointed/re-appointed.
Read the summary - Medium impact
SMS Pharmaceuticals Limited fully utilizes ₹114.30 crore preferential issue proceeds by March 31, 2026
SMS Pharmaceuticals Limited has fully utilized its ₹114.30 crore preferential issue proceeds by March 31, 2026. The funds were allocated towards capital expenditure, working capital, and general corporate purposes. The monitoring agency report confirms full utilization with minor reallocations within approved limits.
Read the summary - Low impact
SMS Pharmaceuticals Confirms Not a Large Corporate as of March 31, 2026
SMS Pharmaceuticals Limited confirms it does not qualify as a 'Large Corporate' as of March 31, 2026, according to SEBI guidelines. Consequently, the company is exempt from certain disclosure requirements related to debt security fundraising.
Read the summary - Medium impact
SMS Pharma Tax Demand Reduced to ₹40.28 Lakhs from ₹7.19 Crore
SMS Pharmaceuticals received a rectification order reducing its tax demand for AY 2018-19 from ₹7.19 crore to ₹40.28 Lakhs. The company filed the rectification application after receiving the initial demand notice. No material impact is expected on operations.
Read the summary - Low impact
SMS Pharmaceuticals Files SEBI Compliance Certificate for Q4 FY26
SMS Pharmaceuticals Limited filed a compliance certificate for the quarter ended March 31, 2026, as per SEBI regulations. The company's RTA confirmed timely dematerialization of securities and compliance with depository procedures.
Read the summary - Medium impact
SMS Pharma receives ₹7.19 Crore Income Tax demand notice for AY 2018-19
SMS Pharmaceuticals Limited received an Income Tax demand notice of ₹7.19 crore for AY 2018-19, dated March 30, 2026. Penalty proceedings for under-reporting income have also been initiated. The company is reviewing the order and expects no material impact on its operations.
Read the summary - Low impact
SMS Pharmaceuticals: Trading Window Closed from April 1, 2026 for Q4FY26 Results
SMS Pharmaceuticals Limited will close its trading window from April 1, 2026. This closure is for designated persons and their relatives and will last until 48 hours after the declaration of the Q4FY26 and FY26 financial results. The board meeting date will be announced later.
Read the summary - Low impact
SMS Pharma Reopens Special Window for Physical Share Transfer Lodgement
SMS Pharmaceuticals Limited has reopened a special window for physical share transfer lodgement. This window, valid from February 5, 2026, to February 4, 2027, is for transfers lodged before April 1, 2019, but rejected or not processed. Shares will be processed via transfer-cum-demat route with a one-year lock-in.
Read the summary - Low impact
SMS Pharma Q3FY26 Monitoring Report: ₹114.30 Cr Proceeds Utilized, No Deviation Noted
SMS Pharmaceuticals Limited's Q3FY26 monitoring report shows ₹114.30 crore raised via warrants. As of Dec 31, 2025, ₹80.93 crore utilized, ₹33.37 crore unutilized. No deviations from objects or finance means. Capex, working capital, and GCP expenses were reported for the quarter.
Read the summary - High impact
SMS Pharma Q3FY26: Revenue Up 21%, PAT Up 29% on Volume Growth
SMS Pharmaceuticals reported Q3FY26 revenue of ₹210.45 crore, up 21% YoY. PAT grew 29% YoY to ₹23.47 crore. For 9MFY26, revenue was ₹648.92 crore (up 21% YoY) and PAT was ₹69.27 crore (up 42% YoY). The company achieved its 10-filing target ahead of schedule and its ₹280 crore capex program is on track for FY27 completion. FY26 outlook remains ~20% revenue growth with EBITDA margins above 20%.
Read the summary - Medium impact
SMS Pharma Q3FY26 Revenue Jumps 21% YoY to ₹210 Cr, PAT Up 29% to ₹23.47 Cr
SMS Pharmaceuticals reported Q3FY26 revenue of ₹210.45 crore, up 21% YoY. PAT increased by 29% to ₹23.47 crore. EBITDA grew 31% to ₹43.65 crore. The company is on track for 20% revenue growth in FY26 with 20% EBITDA margins. A ₹280 crore capex program is progressing well.
Read the summary - Low impact
SMS Pharmaceuticals Limited Publishes Q3 FY26 Financial Results
SMS Pharmaceuticals Limited announced its unaudited standalone and consolidated financial results for Q3 FY26, ending December 31, 2025. The results were published on February 8, 2026, and are also available on the company's website. The Board of Directors approved the results on February 7, 2026.
Read the summary - Low impact
SMS Pharma: No Deviation in Fund Utilization for Preferential Issue
SMS Pharmaceuticals Limited reported no deviation in fund utilization for its preferential issue for the quarter ended December 31, 2025. The company raised ₹1,14,30,00,000 through convertible warrants allotted on March 19, 2024. Warrants were converted into equity shares on March 27, 2025, and September 10, 2025.
Read the summary - Medium impact
SMS Pharma Q3FY26 Results: Profit Declines to ₹233.38 Cr; Approves ₹7 Cr Investment
SMS Pharmaceuticals Limited reported Q3 FY26 results. Standalone net profit was ₹233.38 crore, down from ₹251.43 crore YoY. Consolidated net profit was ₹231.90 crore, down from ₹251.29 crore YoY. The company approved an investment of up to ₹7 crore in its subsidiary, SMS Peptides Private Limited.
Read the summary - Medium impact
SMS Pharma Q3 FY26 Results: Net Profit ₹233.38 Cr, Investment in Subsidiary
SMS Pharmaceuticals Limited reported Q3 FY26 un-audited results. Standalone net profit was ₹23.34 crore and consolidated net profit was ₹23.19 crore for the quarter ended December 31, 2025. The company also approved an investment of up to ₹7 crore in its subsidiary, SMS Peptides Private Limited.
Read the summary - Low impact
SMS Pharmaceuticals Limited: No Share Transfer Requests Processed in Special Window
SMS Pharmaceuticals Limited reports no physical share transfer requests were received, processed, approved, or rejected during the special window period from December 1, 2025, to January 6, 2026, as per SEBI guidelines.
Read the summary - Low impact
SMS Pharmaceuticals Files SEBI Compliance Certificate for Q3 FY26
SMS Pharmaceuticals Limited filed a compliance certificate for the quarter ended December 31, 2025, as per SEBI regulations. The company's RTA confirmed timely dematerialization of securities and updated ownership records.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio